Amyloids are fibrillar protein aggregates that are associated with diseases such as Alzheimer's disease, Parkinson's disease, type II diabetes and Creutzfeldt-Jakob disease. The process of amyloid aggregation involves three pathological protein transformations; from natively-folded conformation to the cross-β conformation, from biophysically soluble to insoluble, and from biologically functional to non-functional.
Introduction
The term amyloid refers to a particular conformational state of proteins where they transform from being soluble and natively-folded into insoluble aggregates of fibrillar nature. More than 35 peptides and proteins are known to form amyloids in different human diseases 1 . Nearly all the proteins that form amyloids have biological functions in their normal, natively-folded state. Some proteins such as antibodies, lipoproteins and serum amyloid A (SAA) lead to systemic amyloidosis including light-chain amyloidosis, Apo-AI amyloidosis and AA amyloidosis, respectively 1 . On the other hand, some proteins accumulate in specific organs leading to localized amyloid pathology. These amyloidopathies include thyroid medullary carcinoma, pulmonary alveolar proteinosis and atrial amyloidosis resulting from the amyloid accumulation of calcitonin, surfactant protein C and atrial natriuretic factor, respectively 1 .
Localized amyloidopathies also include type II diabetes and neurodegenerative diseases such as
Alzheimer's disease (AD), Parkinson's disease (PD). Type II diabetes is characterized by the amyloid accumulation of the peptide hormone islet amyloid polypeptide (IAPP), while AD and PD are characterized by the accumulation of the amyloid beta (Aβ) and alpha syncuclein (α-syn) peptides, respectively 2 . Moreover, AD and other neurodegenerative disease such as frontal temporal dementia with Parkinsonism and Pick's disease involve amyloid aggregates of the microtubule-associated protein tau 3 .
In addition, the amyloid aggregation of the infamous tumor suppressor transcription factor p53 is involved in many cancers 4 . While some amyloids were shown to have beneficial biological function, for example acting as storage for peptide hormones in secretory granules 5 , the vast majority of amyloids are pathological. This explains the existence of several biological protective mechanisms that ensure that proteins are correctly folded such as the presence of chaperones, or degraded when incorrectly folded via processes such as autophagy, ubiquitin-proteasome mediated degradation and the unfolded protein response 6 . Moreover, specific sequence patterns that tend to easily form amyloids, such as alternating hydrophilic-hydrophobic stretches, appear to have been selected against during evolution 7 .
Etiology of amyloidopathies
A small proportion of amyloidopathies is of genetic hereditary origin; however, the majority of amyloid diseases are sporadic 1 . Hereditary forms of amyloidopathies are caused by mutations in the genes encoding the amyloidogenic proteins. Such mutations usually facilitate the aggregation of the amyloidogenic proteins leading to early onset of the disease 8, 9 . For sporadic forms, a small subset of amyloidopathies, termed transmissible spongiform encephalopathies, are caused by infectious protein particles called prions 10 . Prions transfer from one organism to another inducing neurodegeneration in the recipient host in diseases such as Creutzfeldt-Jakob disease and Kuru. For the vast majority of other 4 sporadic forms, the causes are not clear. However, several environmental factors are known to increase disease risk, including infections 11 , lipid dysregulation 12 , pollution 13 and traumatic brain injury 14 .
Amyloid structure
The term amyloid describes a unique class of protein conformation, where proteins adopt an elongated fibrillar morphology. While this is a characteristic feature of pathological protein aggregates, it has been demonstrated that even normal nonpathogenic proteins can be forced to adopt the amyloid conformation under certain denaturing conditions 15 . This led to the "generic hypothesis" suggesting that amyloid formation originates from the fundamental properties of proteins, based on the ability of backbone groups to form hydrogen bonds and the ability of side-chain groups to interact via hydrophobic and van der Waals interactions 16 . To obtain their characteristic morphology, amyloids share a similar core cross-β conformation 17 . In this conformation, the protein molecules are arranged in the form of two oppositely stacked β-sheets, excluding the water molecules in-between and interdigitating their side chains forming a dry steric zipper 2 . Such an elongated cross-β spine constitutes the basic amyloid fibrillar subunit, the protofilament ( Fig. 1) . Apart from the fixed cross-β conformation, protein stacking in the spine can come in a variety of forms. For example, the cross-β architecture can consist of one folded molecule or two separate molecules and the β-sheets can stack in parallel, anti-parallel, face-to-face or face-to-back orientations 17 . Moreover, the protofilament length varies depending on the number strands forming each sheet. Once protofilaments are formed, they can associate in a variety of ways leading to different superstructural polymorphs. These polymorphs include flat fibrillar structures with varied number of horizontally-stacked protofilaments, which can evolve to amyloid crystals, or different twisted ribbon structures (of single or multiple intertwined protofilaments), which can further evolve into nanotubes 18 .
Such superstructural polymorphism depends on many factors including the protein side chain arrangements, the nucleation mechanism (see below) and environmental conditions such as pH and ion concentration 19, 20 . In addition, this biochemical structural transformation is accompanied by a biophysical phase transformation that is dominated by nucleation-growth kinetics as described below. 6
Amyloid nucleation mechanisms
Phase transformation is the process involving transitioning from one state of matter to another, such as liquid to solid or gas to liquid or gas to solid transformations. These transformations are very common in nature, including phenomena such as crystallization and amyloid aggregation (liquid to solid transformation), rain precipitation (gas to liquid transformation) and planet formation (gas to solid transformation) 21, 22 . That is why both the thermodynamics and kinetics of phase transformation have been widely studied. Thermodynamically, the process involves the transition from a less stable (higher free energy) to a more stable (lower free energy) phase under specified conditions 18 . Kinetically, the mechanism of phase transformation involves two steps that are well described by the classical nucleation theory 21 . Initially, a rate-limiting nucleation step takes place, where an energy barrier needs to be overcome to create the initial molecular assembly (nucleus) of the new phase. Once the nucleus is formed, this is followed by a growth step where the system rapidly transforms into the new phase. The nucleationgrowth mechanism accurately describes the kinetics of amyloid formation as studied experimentally, with the distinctive sigmoidal kinetics curve involving a nucleation lag phase followed by a rapid growth or elongation phase 6 ( Figure 1 ).
While nucleus formation is necessary, it is both thermodynamically unfavorable and rare, as it depends on the unlikely event of the spontaneous formation of a stable nucleus of the new phase within the bulk of the transforming phase 2,23 . In the case of amyloid aggregation, this involves the spontaneous conformational change of the protein followed by spontaneous association of protein molecules into cross-β sheet rich nucleus. This pathway to nucleation is called homogenous nucleation (HON) 24 , and with all the protective mechanisms that are in place to maintain proper protein folding (see above), it is not surprising that proteins do not normally reach the amyloid state. In contrast to the slow and rare HON pathway, catalyzed nucleation pathways exist that are faster and more common. One catalytic pathway is called seeding, where adding a preformed nucleus (seed) enables the system to completely bypass the nucleation step and move directly to the growth or elongation step 2 . The other important catalytic pathway is the heterogeneous nucleation mechanism (HEN), where an exogenous surface catalyzes the nucleation process 24, 25 . In HEN, the surface lowers the energy barrier to nucleation and acts a scaffold that facilitates nucleus formation via binding, concentrating and enabling conformational changes in the bound proteins 26, 27 (Fig. 1 ). Like seeding, HEN usually eradicates the lag phase completely from the kinetics. In this regard, many biological and non-biological surfaces have been shown to be capable of HEN, including microbial surfaces 28, 29 , lipid vesicles 30 and nanoparticles 31 . Many polymer surfaces such as glycosaminoglycans (GAGs) 32 and nucleic acids 33 have also been shown to accelerate amyloid aggregation. In addition, the growing fibril surface itself can serve as a site for HEN, in a phenomenon 7 termed secondary nucleation 34 . However, the exact properties of a particular surface that mediate HEN remain poorly understood. Furthermore, the concentration of proteins in intracellular droplets that form via a liquid-liquid phase separation (LLPS) process can sometimes lead to amyloid formation 35 .
Interestingly, low-complexity RNA sequences (CU/AG repeats) have been shown to induce amyloid aggregation within phase-separated liquid droplets, which can have implications for understanding amyloid aggregation in tri/hexa-nucleotide repeat expansion disorders such as Huntington's disease, spinocerebellar ataxias and amyotrophic lateral sclerosis (ALS) 36 . Very recently, Yuan C. et al have demonstrated that the interfaces created by LLPS can act as sites of HEN for amyloids 37 .
A mechanistic approach to etiology
Amyloid aggregation is a process of pathological protein transformation at three levels, a biochemical Here, we propose that different nucleation pathways could also serve as the mechanistic basis for an etiological classification of amyloid pathologies (Fig. 2 ). In this framework, HON is facilitated by mutations that render the protein more prone for spontaneous self-assembly; and hence, is expected to be the dominant mechanism in hereditary amyloidopathies. However, in the normal state, the protein retains its native structure with all the protective mechanisms that prevent proteins from going down the amyloid pathway. In this case, pathogenic catalytic mechanisms are required for the pathological transformation.
This can take place via seeding by a preformed amyloid fragment (prion) whose source can be the same organism due to amyloid fragmentation leading to prion propagation, or a different organism resulting from a prion infection 39 . Alternatively, nucleation can be induced by aberrant surfaces that catalyze HEN.
Such aberrant surfaces can either be of endogenous origin due to a membrane or lipid pathology, or from an exogenous source such as microbes or nanoparticulate pollutants. These HEN catalysts can be responsible for the non-hereditary sporadic disease forms.
While non-protein factors such as exogenous surfaces have usually been considered "co-factors" to a "protein-only" driven process 40 , we emphasize that they are independent causal factors as they promote a distinct and important pathway of amyloid aggregation; HEN. Being thermodynamically more favorable, HEN is more likely to be the prevalent pathway of amyloid aggregation in-vivo in the absence of genetic mutations that can facilitate HON. In this regard, microbes such as viruses and bacteria, which are capable of invading and reproducing in tissues, can be potent mediators of HEN in sporadic amyloidopathies. We have recently shown that viruses such as respiratory syncytial virus (RSV) and
herpes simplex virus type 1 (HSV-1) are able to induce amyloid formation by catalyzing HEN of IAPP and Aβ, respectively 28 pathogens such as bacteria and fungi 41, 42 . This shows that microbes are potent HEN inducers of amyloid aggregation. On the other hand, aberrant membranes may come from endogenous sources. These can be the result of lipid dysregulation involving lipoproteins such as apoE4, which is a known risk factor for AD 43 , or membrane components such as cholesterol, gangliosides and GAGs 32, 44 . Furthermore, membrane fragment microparticles from brain injury 45 can potentially act as catalytic surfaces for HEN mediated amyloid aggregation in traumatic brain injury. Moreover, as has been reported for the amyloid aggregation of insulin 46 , synthetic membranes can act as sites for HEN mediated aggregation of some plasma proteins such as β2 microglobulin in dialysis-related amyloidosis 47 .
It can also be postulated that in some cases HON and HEN mechanisms can overlap, where mutations that would facilitate spontaneous amyloid aggregation via HON can also render the protein more vulnerable [51] [52] [53] . The same applies to Aβ, prion protein (PrP) and α-syn, which are the most studied in the context of neurodegenerative disorders. Soluble Aβ was shown to be important for synaptic plasticity and memory 54 , soluble PrP on the other hand is involved in myelin maintenance and cellular proliferation processes 55 , while α-syn is important for the regulation of neurotransmission and response to cellular stress 56 . Thus, it is expected that these original functions will be lost even before amyloid accumulation reaches substantial toxic GOF levels, and that LOF can at least initially be the neurodegenerative mechanism, as has been suggested previously 56, 57 .
Box 1.
In further support for the importance of LOF diseases mechanisms, in many disease models of amyloid diseases, the knockout animals deficient in the pathogenic protein display disease phenotypes in absence of plaques or aggregates. The importance of LOF is further supported by the fact that in many knockout transgenic models of amyloid diseases, the animals display disease phenotypes in the absence of the amyloidogenic protein and its aggregated forms (Box. 1). Moreover, in AD for example, it has been repeatedly demonstrated that there is not always a correlation between the plaque load and disease severity. This has been shown in animal models 88 and in healthy subjects with significant plaque load without significant cognitive impairment 89 . One way to explain this paradox within a GOF framework has been to postulate that toxicity comes from a not-very-well-defined species called the amyloid oligomers 90 . However, an additional explanation can be the fact that proteins that lose their native conformation will instantly lose their function even if they do not become particularly more toxic, and that such LOF contributes to neuronal degeneration. This is further illustrated by neuronal phenotypes in knockout animal models of several different amyloid pathologies (Box. 1).
Furthermore, it has been recently shown that amyloid fragments (seeds/prions) can propagate pathology from one region to another within the same organism in diseases such as AD and PD 91, 92 . In this case, seeds/prions will induce LOF phase transformation when they encounter a new protein pool. The same can be true for HEN induced by microbes, where the ability of a pathogen to infect a particular area would lead to LOF amyloid transformation in that area. This may explain why in some neurodegenerative diseases the spread of the pathology follows the anatomical connections, which are the same routes for both amyloid fragment and microbial propagation 93, 94 . The LOF framework might also explain the failure of therapeutic approaches aiming only to reduce the amyloid forming proteins and open new directions in treatment that include restoring protein homeostasis via replacement therapy with functional, nonaggregating forms of the protein 95 . Indeed, synthetic IAPP (amylin) analogues such as pramlintide are clinically used as replacement therapy in diabetes 53 . Furthermore, overexpression of soluble amyloid precursor protein alpha (APPsα) has been shown to restore synaptic plasticity, reduce soluble Aβ and plaque load and rescue spatial memory in an AD mouse model with preexisting pathology and amyloidosis 96 . This demonstrates that replacement therapy within a LOF framework is a promising approach; one that can be extended to other amyloidopathies.
Phase transformation or replication?
The amyloid aggregation phenomenon, especially in the context of prions, is sometimes referred to as a process of protein "self-replication" that is dominated by a "protein-only" species leading to different prion "strains" that possess different pathogenic potentials 50 . Here, we would like to argue that the phenomenon of amyloid aggregation is better described in physical terms rather than biological terms that imply information preservation and transfer via replication and strain diversity. Amyloid aggregation is a process of nucleation-dependent phase transformation that is very common in nature similar to crystal growth or rain precipitation in non-biological systems. Moreover, other normal biological processes such as biomineralization of hard tissues 97 and the assembly of actin or tubulin 98, 99 are also dominated by nucleation-dependent mechanisms. However, in these normal biological processes, protein subunits assemble in their native rather than unfolded cross-β conformation. While many of these non-organic and organic phenomena share similar features with amyloids such as self-assembly, repeated patterns and superstructural polymorphism, in none of these cases is the process referred to as "self-replication" in the biological sense of the word. Moreover, polymorphic heterogeneity is dependent on the nucleation mechanism and environmental factors (such as pH and temperature); factors that are not encoded in the core molecular conformation; and hence, cannot be faithfully replicated. Importantly, nucleation reactions take place via HEN, where no information is transferred from the catalyzing surface to the growing fiber, while still affecting superstructural polymorphism. This lack of information preservation or transfer indicates that the amyloid/prion phenomenon cannot be compared to the nucleic acids in terms of biological replication; which in the case of nucleic acids, is dominated by well-controlled mechanisms and machinery that ensure preservation and faithful replication of the genetic information.
We are aware that the "protein-only" hypothesis of protein "self-replication" was initially introduced to distinguish amyloids from viral infections based on the absence of nucleic acids within amyloids 100 .
Despite the historical importance of such distinction, it does not imply that the amyloid phenomenon should always be understood within the bounds of this historical dichotomy. Structural and biophysical studies of amyloids in recent years have uncovered important details about the common structural features of amyloids and the different physical pathways of their aggregation (see above). Many of these new advances do not fit easily within the "protein-only" paradigm. This is particularly apparent in relation to HEN phenomena, which can be mediated by viral and other microbial surfaces; the very species the "protein-only" hypothesis was supposed to exclude from the pathology. HEN also clearly demonstrates the lack of information transfer during the amyloid aggregation process. That is why a new synthesis of the available data was necessary to accommodate for these findings. In that sense, we think that the nucleation-based classification of amyloid pathologies that we describe here does offer a more accurate and inclusive attempt to describe the multifactorial nature of amyloid aggregation using a well-defined physical framework.
One advantage of this physical classification is that it provides a mechanistic explanation of phenomena that are currently unaccounted for within the "protein-only" paradigm, including the sporadic forms of the disease. It allows the integration of risk factors (such as lipid pathology, infections and pollution) into the core of the pathogenesis via a well-defined mechanism. Furthermore, by highlighting the common physical foundations of the amyloid aggregation process, it becomes much easier to find correlations and common mechanisms between different amyloid pathologies that have been studied separately in isolated disease contexts. This creates a logical framework where data from different diseases can be integrated into a more general understanding. One outcome of such general understanding is that HEN and LOF mechanisms assume a more clear and prominent role in disease etiology and pathophysiology, opening new opportunities for novel diagnostic and therapeutic modalities. This is particularly important at a time where the failure of previous therapeutic interventions calls for new ways to understand amyloid pathologies.
In relation to novel diagnostics, HEN pathways are expected to contribute to amyloid polymorphism (see above), which can help in the differential histopathological diagnosis by relating particular amyloid polymorphs to certain HEN interactions. This may enable the development of new therapeutic interventions to specifically target these interactions, or preventive measures such as vaccines targeting specific microbes involved in HEN-mediated amyloid induction. In addition, highlighting the LOF angle of the pathology can lead to new treatments that aim to restore the original protein functions via different replacement therapy approaches.
Conclusions: Pathological Nucleation and Solidification of Soluble Proteins
In this perspective article, we link amyloid etiologies to the physical mechanisms of nucleation. We point out that familial mutations facilitate spontaneous aggregation, leading to HON dominated mechanisms.
The sporadic forms on the other hand may rely more on catalytic nucleation mechanisms, either via prion seeding or HEN. HEN mechanisms, in turn, can be mediated by a plethora of aberrant membranes, among which microbial membranes such as viruses and bacteria may be of critical importance, due to their ability to invade and replicate in various tissues. Moreover, we think that amyloids are more precisely described in physical terms similar to other organic and non-organic phase transformations, rather than in biological terms that invoke self-replication and biological strains. Furthermore, biochemical and biophysical amyloid transformations may lead to LOF toxicity due to loss of solubility and native protein conformation, even if the resulting aggregates are not particularly more toxic. Such a generalized framework for a mechanistic-based understanding can open new avenues for the exploration of new measures to diagnose, prevent and treat amyloidopathies.
